Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
13
Stocks News & Analysis
stocks
Ahead of an IPO, the maths behind Databrick’s $190 billion valuation doesn’t add up
stocks
Takeover proposal agreed for ASX share, other offers permitted
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,927.80 | 8.70 | 0.10% |
| CAC 40 | 8,138.94 | 73.92 | 0.92% |
| DAX 40 | 25,575.01 | 270.95 | 1.07% |
| Dow JONES (US) | 52,048.83 | 366.19 | 0.71% |
| FTSE 100 | 10,739.01 | 79.88 | 0.75% |
| HKSE | 25,143.45 | 100.74 | 0.40% |
| NASDAQ | 27,122.09 | 599.55 | 2.26% |
| Nikkei 225 | 65,018.95 | 882.70 | 1.38% |
| NZX 50 Index | 13,833.69 | 12.49 | 0.09% |
| S&P 500 | 7,764.70 | 114.20 | 1.49% |
| S&P/ASX 200 | 8,735.70 | 3.80 | 0.04% |
| SSE Composite Index | 3,958.64 | 8.73 | 0.22% |